Allergan PLC. (NYSE:AGN) Director Chris W. Bodine acquired 3,030 shares of Allergan stock in a transaction dated Thursday, December 7th. The shares were acquired at an average price of $164.77 per share, with a total value of $499,253.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Allergan PLC. (NYSE:AGN) traded up $3.72 during trading hours on Thursday, hitting $168.00. 3,660,200 shares of the stock traded hands, compared to its average volume of 2,935,009. Allergan PLC. has a 12-month low of $160.07 and a 12-month high of $256.80. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The stock has a market cap of $54,636.75, a PE ratio of 10.65, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11.

Allergan (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same period last year, the company posted $3.32 EPS. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. equities research analysts expect that Allergan PLC. will post 16.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 annualized dividend and a dividend yield of 1.67%. Allergan’s payout ratio is -12.44%.

Allergan announced that its board has authorized a share repurchase plan on Monday, September 25th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Several research analysts have weighed in on the stock. J P Morgan Chase & Co set a $275.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Sunday, October 22nd. Morgan Stanley cut shares of Allergan from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $284.00 to $228.00 in a report on Wednesday, September 20th. Cowen reaffirmed an “outperform” rating and set a $400.00 target price on shares of Allergan in a report on Tuesday, August 29th. Zacks Investment Research lowered shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Finally, Cantor Fitzgerald reduced their price target on shares of Allergan to $191.00 and set a “neutral” rating on the stock in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $235.25.

A number of large investors have recently added to or reduced their stakes in the business. Bank of Nova Scotia raised its position in shares of Allergan by 77.2% during the first quarter. Bank of Nova Scotia now owns 147,160 shares of the company’s stock valued at $35,160,000 after buying an additional 64,116 shares during the last quarter. North Star Asset Management Inc. increased its position in Allergan by 1.9% during the first quarter. North Star Asset Management Inc. now owns 26,875 shares of the company’s stock valued at $6,421,000 after acquiring an additional 503 shares during the last quarter. Community Trust & Investment Co. increased its position in Allergan by 5.0% during the first quarter. Community Trust & Investment Co. now owns 49,518 shares of the company’s stock valued at $11,831,000 after acquiring an additional 2,339 shares during the last quarter. Achmea Investment Management B.V. bought a new position in Allergan during the first quarter valued at $5,824,000. Finally, Bristlecone Advisors LLC increased its position in Allergan by 6.6% during the first quarter. Bristlecone Advisors LLC now owns 10,566 shares of the company’s stock valued at $2,524,000 after acquiring an additional 650 shares during the last quarter. Institutional investors and hedge funds own 81.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with's FREE daily email newsletter.